证券代码：000915 证券简称：华特达因 公告编号： 2025-027 山东华特达因健康股份有限公司 关于股东持股比例增加至5%以上权益变动的 提示性公告 公司股东郭伟松保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与郭伟松先生提供的信 息一致。 特别提示： 年6月17日收到股东郭伟松先生出具的《山东华特达因健康股份有限 公司简式权益变动报告书》。本次权益变动后，郭伟松先生持有公司 股份为11,716,624股，占公司当前总股本的5.00%； 一、本次增持情况 姓名 郭伟松 曾用名 无 性别 男 国籍 中国 身份证号 3505241974******** 住所及通讯地址 福建省厦门市思明区******** 是否取得其他国家或 是 地区的居留权 本次权益变动是郭伟松先生基于对公司价值分析及前景的预测 而做出，希望与公司建立长期稳定的投资关系并获取投资收益。本次权 益变动不以谋求公司的控制权为最终目的。 增持均价 增持股数 增持日期 增持方式 股份种类 增持比例 （元/股） （股） 集中竞价 29.19 24,400 普通股 0.01% 本 ...

Group 1 - Over 1500 companies have completed their dividend distribution for the year 2024, with 1532 companies having implemented their dividend plans as of June 9 [2][3] - Companies such as Haibo Sichuang, Lizhu Group, Huate Dain, and Midea Group are among those with the highest proposed dividend amounts per share [2][3] - Midea Group plans to distribute 35 yuan in cash for every 10 shares, with the record date on June 11, 2025, and the payment date on June 12, 2025 [2][3] Group 2 - Renhe Pharmaceutical announced a cash dividend of 1.5 yuan per 10 shares, with the record date on June 16, 2025, and the payment date on June 17, 2025 [3] - Haibo Sichuang plans to distribute a cash dividend of 1.1 yuan per share, with the record date on June 12, 2025, and the payment date on June 13, 2025 [4] Group 3 - Several companies are announcing mid-term dividend plans, with Zhangjiang Hi-Tech proposing to increase mid-term cash dividends based on profitability and cash flow [5][6] - High New Development is seeking authorization to establish a mid-term dividend plan for 2025, emphasizing the need for positive earnings and cash flow [6] Group 4 - The Shanghai Stock Exchange held a meeting to discuss enhancing high dividend and high yield company valuations, indicating a push for increased dividend distributions [7] - Experts suggest that dividends can boost investor confidence and reflect a company's cash strength and profitability [7]

Core Viewpoint - The participation of minority shareholders in corporate governance is increasing significantly in the A-share market, driven by legal enhancements, rising awareness of shareholder rights, and the internal need for improved corporate governance [1][7]. Group 1: Minority Shareholder Proposals - Several minority shareholders have submitted temporary proposals to various companies, including Donghua Energy (2.01% ownership), Hengli Drilling (1.45%), and *ST Jingfeng (1.26%), indicating a trend of active engagement [1][2]. - Companies like ST Kelly and others have also seen proposals from shareholders holding over 3% of shares, although not all proposals have been approved for discussion at shareholder meetings [3][4]. Group 2: Regulatory Changes - The new company law effective from July 1, 2023, has lowered the threshold for submitting temporary proposals from 3% to 1%, enhancing the rights of minority shareholders [5][7]. - Following the regulatory changes, numerous companies have amended their articles of association to reflect the new 1% threshold for proposal submissions [6]. Group 3: Implications of Increased Participation - The active involvement of minority shareholders is expected to improve corporate governance structures by providing diverse perspectives and opinions, thus addressing potential limitations of major shareholders and management [7]. - Minority shareholder proposals can serve as a check on the power of major shareholders and management, promoting fairness and justice in corporate decision-making [7]. - The engagement of minority shareholders is likely to enhance the quality of corporate decisions, as they may bring different expertise and insights to the table [7]. - This trend also reflects greater transparency and democracy in corporate governance, potentially boosting investor confidence and improving the company's reputation in the capital market [8].

Group 1 - The company approved a profit distribution plan at the annual shareholders' meeting held on May 13, 2025, proposing a cash dividend of 20.00 yuan (including tax) for every 10 shares, resulting in a total cash dividend of 468,662,970.00 yuan for the 2024 fiscal year [1][2] - The distribution plan specifies that the cash dividend will not involve capital reserve transfers or stock bonuses, and the total share capital remains unchanged during the implementation period [1] - The dividend distribution will be executed on June 11, 2025, directly credited to shareholders' accounts through their securities companies or other custodians [3] Group 2 - The equity distribution is applicable to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shenzhen Branch as of June 10, 2025 [1][3] - The company will not withhold individual income tax for certain shareholders, with tax rates varying based on the holding period of the shares [2][3] - The company assumes all legal responsibilities for any insufficient cash dividend distribution during the equity distribution application period [3]

证券代码：000915 股票简称：华特达因 编号：2025-026 山东华特达因健康股份有限公司 2024 年度权益分派实施公告 本公司及其董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、股东会审议通过的利润分配方案情况 1．山东华特达因健康股份有限公司（以下简称"本公司"或"公司"） 于 2025 年 5 月 13 日召开公司 2024 年年度股东会，审议通过了"公司 2024 年度利润分配及资本公积金转增股本预案"：以 2024 年 12 月 31 日的总股本 234,331,485 股为基数，向公司全体股东每 10 股派发现金 红利 20.00 元（含税），不以资本公积金转增股本，不送红股。2024 年度实际现金分红金额为 468,662,970.00 元人民币。（现金分红总金 额=实际参与分配的总股本×分配比例，即 234,331,485 股÷10 股×20.00 元=468,662,970.00 元人民币） 2．公司本次利润分配为固定比例方式分配。自分配方案披露至 实施期间，公司股本总额未发生变化。 3．本次实施的分配方案与公司 2024 年年度股东会审 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司子公司山东达因海洋生物制药股 份有限公司（以下简称"达因药业"）近日收到国家药品监督管理局（以 下简称"国家药监局"）核准签发的《药物临床试验批准通知书》。现将 有关信息披露如下： | 药物名称 | 异丙托溴铵吸入气雾剂 | | --- | --- | | 批件类别 | 药物临床试验批准通知书 | | 受理号 | CXHL2500061 | | 批件号 | 2025LP01446 | | 剂型 | 气雾剂 | | 申请事项 | 国产药品注册 | | 注册分类 | 化学药品注册分类 4 类 | | 申请人 | 山东达因海洋生物制药股份有限公司 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规定，经审查，符 合药品注册的有关要求，同意本品开展用于预防和治疗与慢 性阻塞性气道疾病相关的呼吸困难：慢性阻塞性支气管炎伴 或不伴有肺气肿；轻到中度支气管哮喘的临床试验。 | 一、药物临床试验批准通知书基本内容 证券代码：000915 证券简称：华特达因 公告编号：2025-025 山东 ...

Core Viewpoint - The company, Watson, has received approval from the National Medical Products Administration for a clinical trial of a new drug, indicating a significant step in its product development pipeline [1] Group 1: Drug Approval - Watson's subsidiary, Dain Pharmaceutical, has been granted a "Drug Clinical Trial Approval Notice" for the drug named Isopropyl Bromide Inhalation Aerosol [1] - The drug is classified as a Class 4 chemical drug and is intended for the prevention and treatment of respiratory difficulties associated with chronic obstructive airway diseases, chronic bronchitis with or without emphysema, and mild to moderate bronchial asthma in both children and adults [1] Group 2: Next Steps - Following the approval of the clinical trial, the company must conduct clinical trials before applying for production and market approval from the National Medical Products Administration [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：000915 证券简称：华特达因 公告编号：2025-024 山东华特达因健康股份有限公司 关于子公司达因药业获得药品注册证书的公告 三、获得药品注册证书对公司的影响及风险提示 药品名称 丙戊酸钠口服溶液 主要成分 丙戊酸钠 剂型 口服溶液剂 申请事项 药品注册（境内生产） 规格 40ml：8g 注册分类 化学药品 4 类 药品注册标准编号 YBH10372025 药品有效期 24 个月 包装规格 1 瓶/盒 处方药/非处方药 处方药 上市许可持有人 山东达因海洋生物制药股份有限公司 生产企业 山东达因海洋生物制药股份有限公司 药品批准文号 国药准字 H20254187 药品批准文号有效期 至 2030 年 05 月 12 日 一、 药品注册证书基本情况 达因药业获得丙戊酸钠口服溶液 药品注册证书》，进一步丰富 了公司儿童用药产品管线，有助于公司发展战略的实现和竞争力的增 强，对公司致力于儿童健康事业和业绩的提升将产生积极影响。 药品销售易受到国内医药行业政策变动、招标采购、市场环境变 化等因素影响，存 ...

Group 1: Company Mission and Product Development - The company aims to become a leader in children's health and treatment, focusing on building a comprehensive research and development system for pediatric medications [1][2] - It plans to launch an average of 1-2 new pediatric medications annually, with key research areas including respiratory, mental health, and rare diseases [1][2] - The flagship product, Vitamin AD, holds a market share of over 60%, and the company is expanding its product line to meet diverse health needs [1][2] Group 2: Financial Performance and Dividends - The company has maintained a high dividend payout, with the amount distributed to shareholders in the last two years accounting for 95.79% of net profit attributable to the parent company [7] - For the 2024 fiscal year, the total dividend amount reached 119% of the net profit after deducting non-recurring gains [7] - The company is committed to sharing its growth with shareholders through substantial dividends, contingent on stable operational performance [4][7] Group 3: Market Strategy and Product Positioning - The company will adhere to a core marketing strategy focused on expert recommendations, convenient purchasing channels, and professional education [2][4] - It aims to enhance its market presence through all-channel marketing and new retail strategies, targeting pharmacies and e-commerce platforms [2][4] - Continuous optimization of product structure and increased R&D investment are planned to introduce more competitive products [2][4] Group 4: Stakeholder Engagement and Future Outlook - The controlling shareholder plays a significant role in strategic development and resource allocation, although no social security funds have conducted on-site research [3][4] - The company is open to suggestions for entering new product categories, such as children's diapers, but currently has no plans to do so [4][5] - Future product development will focus on maintaining a competitive edge in the children's health sector while ensuring compliance and quality [4][5]

Core Viewpoint - In 2024, Huate Dain experienced its first decline in revenue and net profit after five consecutive years of growth, but showed signs of recovery in Q1 2024 with a revenue of 616 million yuan, up 7.78%, and a net profit of 182 million yuan, up 8.13% [1] Group 1: Company Performance - Huate Dain's General Manager Yang Jie indicated that the company faced intensified market competition in 2024, leading to performance fluctuations, but efforts to focus on core pharmaceutical operations are expected to yield positive results starting from Q4 2024 [1] - The company successfully addressed issues related to terminal sales pressure through ongoing marketing activities and the expansion of new retail business [1] Group 2: Subsidiary Performance - The main revenue and profit source for Huate Dain is its subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd. (Dain Pharmaceutical), which optimized its intelligent production system in 2024, enhancing both production efficiency and product quality [2] - Dain Pharmaceutical expanded the applicable age for its product Yikexin from 0-6 years to 0-18 years, tapping into the middle and older children's market, while also promoting other vitamin and therapeutic drugs [2] Group 3: Market Trends and Strategies - The demand for children's health is evolving beyond disease treatment to include nutrition, daily care, and mental health, indicating a growing market space [2] - Dain Pharmaceutical formed a strategic partnership with Duomeikang (Beijing) Biopharmaceutical Co., Ltd. to explore children's skin health, launching new product lines to meet differentiated needs [2][3] - The collaboration with Duomeikang is seen as a move towards a more comprehensive solution in children's health, emphasizing specialized depth and ecological collaboration as key growth paths for the industry [3]